Extended Data Fig. 8: Overall survival in patients with KMT2Ar or mutated NPM1.
From: The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
OS, overall survival.
Extended Data Fig. 8: Overall survival in patients with KMT2Ar or mutated NPM1. | Nature
